Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Simon Harrison

Simon Harrison

MBBS, MRCP(uk), FRCPath(uk), FRACP, PhD
Peter MacCallum Cancer Centre
Defining high-risk multiple myeloma: recent advances in the field & future considerations
Francesco Maura et al. • 4 Nov 2024
Genetic biomarker use in myeloma: Updates from ASH 2020 1:57
Genetic biomarker use in myeloma: Updates from ASH 2020
Simon Harrison • 7 Dec 2020
Cevostamab (BFCR4350A): a novel bispecific antibody in R/R myeloma therapy 1:56
Cevostamab (BFCR4350A): a novel bispecific antibody in R/R myeloma therapy
Simon Harrison • 7 Dec 2020
AMG 701 shows promise in heavily pre-treated myeloma patients 1:30
AMG 701 shows promise in heavily pre-treated myeloma patients
Simon Harrison • 7 Dec 2020
The content of VJHemOnc is intended for healthcare professionals